There have been several developments in modern medicine linked to AI technologies in the past couple years. One of the most recent has enabled scientists and medical professionals to accurately identify brain tumours in a more timely manner.
To accomplish this, researchers from the American National Cancer Institute (NCI) and Canberra’s Australian National University created an AI tool called DEPLOY. They say it has a 95 per cent level of accuracy, based on its examination of thousands of datasets. It can even recognize tumours that are considered to be the most difficult to classify.
The journal Nature Medicine published a study on the matter last week.
Current diagnostic methods used to distinguish different types of brain cancers are accurate, but can take several weeks to yield results. This is problematic given the time sensitivity of the issue and the need for immediate treatment to prevent further damage and potentially death among those with the condition.
“The technique is very time consuming,” Dan-Tai Hoang, a researcher at the NCI, told Voice of America on Monday. “It is often around two to three weeks to obtain a result from the test, whereas patients with high-grade brain tumours often require treatment as soon as possible because time is the goal for the tumours.”
🧠 Exciting news! Researchers from ANU have developed DEPLOY, a groundbreaking AI tool for quicker and more accurate brain tumour classification. With 95% accuracy, it could revolutionise patient treatment. 🙌
🖇️ Learn more about this research: https://t.co/vnzbKdMIri pic.twitter.com/KElHmNzIoH
— anualumni (@ANUAlumni) May 20, 2024
Read more: Verses announces Genius public beta preview and webinar June 20
Read more: Verses AI onboards chief product officer in push for AI product Genius
Toronto scholars undertake similar initiative
Researchers from Toronto Metropolitan University have developed an AI tool for the same purpose. The institution says it uses a deep learning algorithm to accurately analyze MRI scans and brain images with mathematics.
“Using AI for brain tumour diagnosis and management could lead to more personalized therapeutic regimes which ultimately improve quality of care,” the school’s professor and AI expert April Khademi said last month.
Artificial intelligence has become increasingly important for understanding human biology more comprehensively. Programs developed to enhance our understanding of the body and nature more broadly include Genius, developed by Verses AI Inc. (CBOE: VERS) (OTCQB: VRSSF), and Google DeepMind’s AlphaFold system.
Verses AI is a sponsor of Mugglehead news coverage
rowan@mugglehead.com
